ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1

Leukemia

Volumn 25, Issue 2, 2011, Pages 290-300

  Thai, M ^a   Ting, P Y ^a   McLaughlin, J ^a   Cheng, D ^a   Muschen M ^b   Witte, O N ^a   Colicelli, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BCR ABL1; CML; imatinib; Ras; resistance; RIN1

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; GROWTH FACTOR; IMATINIB; RIN1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CATALYSIS; CELL TRANSFORMATION; CONFORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE FUSION; GENE SILENCING; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

EID: 79751534043     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.268     Document Type: Article

References (56)

1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22: 247-306. (Pubitemid 38680424)
2. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-38.
3. Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada N et al. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 2000; 95: 2126-2131. (Pubitemid 30151655)
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653. (Pubitemid 40446252)
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (NY) 2001; 293: 876-880. (Pubitemid 32743979)
6. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
7. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562-2569. (Pubitemid 47494357)
8. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506. (Pubitemid 351763902)
9. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959-10966. (Pubitemid 44876995)
10. Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res 2007; 67: 11576-11584.
11. Wu LX, Xu JH, Zhang KZ, Lin Q, Huang XW, Wen CX et al. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008; 22: 1402-1409. (Pubitemid 352006084)
12. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14: 238-249.
13. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010; 18: 74-87.
14. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002; 32: 201-205. (Pubitemid 34977219)
15. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458: 776-779.
16. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112: 859-871. (Pubitemid 36378887)
17. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002; 108: 247-259. (Pubitemid 34161144)
18. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006; 21: 787-798. (Pubitemid 43376129)
19. Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 2000; 275: 35631-35637.
20. Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 2001; 20: 8075-8084. (Pubitemid 34030578)
21. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400-2411. (Pubitemid 29453611)
22. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol 2003; 23: 3884-3896. (Pubitemid 36597467)
23. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16: 4107-4116. (Pubitemid 26251210)
24. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
25. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12: 27-37. (Pubitemid 36945035)
26. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990; 87: 6649-6653.
27. Cao X, Tanis KQ, Koleske AJ, Colicelli J. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms. J Biol Chem 2008; 283: 31401-31407.
28. Hu H, Bliss JM, Wang Y, Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol 2005; 15: 815-823. (Pubitemid 40689399)
29. Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K et al. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 1997; 6: 773-782. (Pubitemid 27305739)
30. Hu H, Milstein M, Bliss JM, Thai M, Malhotra G, Huynh LC et al. Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration. Mol Cell Biol 2008; 28: 1573-1583.
31. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558-6562.
32. Hardy RR, Hayakawa K. B-lineage differentiation stages resolved by multiparameter flow cytometry. Ann N Y Acad Sci 1995; 764: 19-24. (Pubitemid 26136137)
33. Klemm L, Duy C, Iacobucci I, Kuchen S, Von Levetzow G, Feldhahn N et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232-245.
34. Mardiney III M, Malech HL. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 1996; 87: 4049-4056. (Pubitemid 26152247)
35. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (NY) 2000; 289: 1938-1942.
36. Dzudzor B, Huynh L, Thai M, Bliss JM, Nagaoka Y, Wang Y et al. Regulated expression of the Ras effector Rin1 in forebrain neurons. Mol Cell Neurosci 2010; 43: 108-116.
37. Dhaka A, Costa RM, Hu H, Irvin DK, Patel A, Kornblum HI et al. The RAS effector RIN1 modulates the formation of aversive memories. J Neurosci 2003; 23: 748-757. (Pubitemid 36206165)
38. Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007; 21: 1363-1377. (Pubitemid 46965277)
39. Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci USA 2003; 100: 11630-11635. (Pubitemid 37205987)
40. Wang JY, Ledley F, Goff S, Lee R, Groner Y, Baltimore D. The mouse c-abl locus: molecular cloning and characterization. Cell 1984; 36: 349-356. (Pubitemid 14126226)
41. Okabe M, Matsushima S, Morioka M, Kobayashi M, Abe S, Sakurada K et al. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosomepositive acute lymphocytic leukemia. Blood 1987; 69: 990-998. (Pubitemid 17080913)
42. Morikawa J, Li H, Kim S, Nishi K, Ueno S, Suh E et al. Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARalpha). Int J Oncol 2003; 23: 617-625.
43. de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83: 271-285. (Pubitemid 36255371)
44. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 2006; 103: 19466-19471. (Pubitemid 46026054)
45. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999; 19: 6918-6928. (Pubitemid 29441874)
46. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998; 91: 406-418. (Pubitemid 28053362)
47. Clark SS, Chen E, Fizzotti M, Witte ON, Malkovska V. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J Virol 1993; 67: 6033-6046. (Pubitemid 23277514)
48. Chen S, O'Reilly LP, Smithgall TE, Engen JR. Tyrosine Phosphorylation in the SH3 Domain Disrupts Negative Regulatory Interactions within the c-Abl Kinase Core. J Mol Biol 2008; 383: 414-423.
49. Barbieri MA, Kong C, Chen PI, Horazdovsky BF, Stahl PD. The SRC homology 2 domain of Rin1 mediates its binding to the epidermal growth factor receptor and regulates receptor endocytosis. J Biol Chem 2003; 278: 32027-32036. (Pubitemid 37048391)
50. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L et al. RIN1 is a breast tumor suppressor gene. Cancer Res 2007; 67: 11510-11516.
51. Tomshine JC, Severson SR, Wigle DA, Sun Z, Beleford DT, Shridhar V et al. Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines is dependent on RIN1. J Biol Chem 2009; 284: 26331-26339.
52. Weng AP, Ferrando AA, Lee W, Morris JPT, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (NY) 2004; 306: 269-271. (Pubitemid 39336870)
53. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002; 16: 2252-2263. (Pubitemid 35013088)
54. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843. (Pubitemid 36378885)
55. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010; 116. E-pub ahead of print (PMID 20519627).
56. Han L, Colicelli J. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1. Mol Cell Biol 1995; 15: 1318-1323.